Hims & Hers Shares after the Food and Drug Administration says he says that fatty fat is no longer a shortage

shares Hims & Rels Health More than 23 % fell on Friday after the US Food and Drug Administration Declare The shortage of hungry injection products has been resolved.

Semaglutide is the active ingredient in Novo Nordsk‘ These medications are part of a category of medicines called GLP-1S, and the demand for treatments has exploded in recent years. As a result, digital health companies such as HIMS & HERS describes the compound Smaglutide as an alternative to patients who move in volatile obstacles and insurance obstacles.

Complex medications phrase loss. Food and Drug Administration Unworthy Safety and effectiveness of compound products.

HIMS & HERS started introducing SMAGLUTIDE to patients in MayAnd it owns complex pharmacies that produce medicines.

Complex medications are usually much cheaper than their branded counterparts. Hims & Hers Smaglutide sells the compound for less than $ 200 per month, while both OzemPIC and Wegov cost about $ 1,000 per month without insurance.

The FDA said on Friday that it will start taking action against the two compounds due to violations in the next sixty to 90 days, depending on the type of facility, in order to “avoid unnecessary disorder to treat the patient.”

“Now that the Food and Drug Administration (FDA) has determined that the lack of drugs in the vocalty in the hoodyd, we will continue to provide access to customized treatments as permitted to meet the needs of patients.” Friday was published on x. “We are also closely monitoring the potential shortage in the future, as Novo Nordisk reported two weeks ago that it will continue to obtain” capacity restrictions “and” expected periodic supply restrictions and relevant drug deficiency notifications. “

His performance was losing his weight and has a tremendous success with investors. The shares of the company rose more than 200 % last year, and the stock has already increased more than 100 % this year despite the movement on Friday.

Even before Glp-1 added the vehicle to its wallet, the company said in it 2023 Fourth quarter profits Calling is expected that the weight loss program will achieve more than $ 100 million at the end of 2025.

Despite the turbulent organizational scene, Hims & HERS did not show any signs of slowdown.

Friday, the company Declare It has acquired the US -based peptide facility that “will increase the company’s long -term ability to provide custom medications.” HIMS & HERS will explore progress by improving metabolism, recovery science, biological resistance, cognitive performance, and preventive health through acquisition, The company said.

This step comes just days after Hims and also Tybe LabsLaboratory test at home in New Jersey. Tybe Labs He will allow him Performing clouds at home at home And the most comprehensive treatment test.

HIMS & HERS did not reveal the terms of any of the deal.

He watches: Hims & Hers Super Bowl Ad Sparks controversy